Refractory Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3450
Buy Report

Published: November 28, 2024 Report Code: GDHC7175CTIDB-ST

Select Item

Refractory Multiple Myeloma Clinical Trial Report Overview

A total of 1726 refractory multiple myeloma clinical trials were conducted as of November 2024. The refractory multiple myeloma clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials.

Key Regions ·       Asia-Pacific

·       North America

·       Europe

·       Middle East and Africa

·       South and Central America
Key Countries ·       The US

·       China

·       Spain

·       Japan

·       The UK
Key Sponsor Types ·       Company

·       Institution

·       Government
Leading Sponsors ·       Bristol-Myers Squibb Co

·       Johnson & Johnson

·       Takeda Pharmaceutical Co Ltd

·       Amgen Inc

·       Pfizer Inc
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Refractory Multiple Myeloma Clinical Trials Segmentation by Regions and Countries

As of November 2024, North America led the refractory multiple myeloma clinical trials landscape with more than 40% of the clinical trials conducted there

A few of the key regions considered for refractory multiple myeloma clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.

In the country-wise analysis, the US had the highest number of refractory multiple myeloma clinical trials as of November 2024. The UK had the highest average patient enrollment in refractory multiple myeloma clinical trials during the same time.

G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, Germany had the highest proportion of refractory multiple myeloma to oncology clinical trials as of November 2024.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey had the highest proportion of refractory multiple myeloma to oncology clinical trials as of November 2024.

Refractory Multiple Myeloma Clinical Trials Analysis by Regions, 2024 (%)

Refractory Multiple Myeloma Clinical Trials Analysis by Regions, 2024 (%)

Buy the Full Report for More Regional Insights into the Refractory Multiple Myeloma Clinical Trials
Download a Free Sample Report

Refractory Multiple Myeloma Clinical Trials Segmentation by Sponsor Types

The key sponsor types for refractory multiple myeloma clinical trials are company, institution, and the government. As of November 2024, the company sponsor type conducted more than 51% of refractory multiple myeloma clinical trials.

Refractory Multiple Myeloma Clinical Trials Analysis by Sponsor Types, 2024 (%)

Refractory Multiple Myeloma Clinical Trials Analysis by Sponsor Types, 2024 (%)

Buy the Full Report for More Sponsor Type Insights into the Refractory Multiple Myeloma Clinical Trials

Download a Free Sample Report

Refractory Multiple Myeloma Clinical Trials - Competitive Landscape

A few of the leading sponsors for refractory multiple myeloma clinical trials are:

  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Takeda Pharmaceutical Co Ltd
  • Amgen Inc
  • Pfizer Inc

In 2024, Bristol-Myers Squibb Co conducted the highest number of refractory multiple myeloma clinical trials.

Refractory Multiple Myeloma Clinical Trials Analysis by Sponsors, 2024 (%)

Refractory Multiple Myeloma Clinical Trials Analysis by Sponsors, 2024 (%)

Buy the Full Report to Know More about the Leading Sponsors of Refractory Multiple Myeloma Clinical Trials

Download a Free Sample Report

Segments Covered in the Report

Refractory Multiple Myeloma Clinical Trials Regional Outlook (2024)

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South and Central America

 Refractory Multiple Myeloma Clinical Trials Country Outlook (2024)

  • The US
  • China
  • Spain
  • Japan
  • The UK

 Refractory Multiple Myeloma Clinical Trials Sponsor Type Outlook (2024)

  • Company
  • Institution
  • Government

Scope

  • The report provides a snapshot of the global clinical trials landscape.

  • The report outlines top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.

  • The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.

  • The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for unaccomplishment.

  • The report delves into the enrollment trends for the past five years.

  • The report provides the latest news for the past three months.

Reasons to Buy

  • Assists in formulating key business strategies with regard to investment.

  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.

  • Provides top-level analysis of global clinical trials market which helps in identifying key business opportunities.

  • Supports understanding of trial count and enrollment trends by country in the global therapeutics market.

  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.

  • Facilitates clinical trial assessment of the indication on a global, regional, and country level.

Table of Contents

  • 1. Table of Contents

    • 1.1. List of Tables

    • 1.2. List of Figures

  • 2. Report Guidance

  • 3. GlobalData Clinical Trials Report Coverage

  • 4. Clinical Trials by Region

    • 4.1. Clinical Trials and Average Enrollment by Country

      • 4.1.1. Top Five Countries Contributing to Clinical Trials in Asia-Pacific

      • 4.1.2. Top Five Countries Contributing to Clinical Trials in Europe

      • 4.1.3. Top Countries Contributing to Clinical Trials in North America

      • 4.1.4. Top Five Countries Contributing to Clinical Trials in Middle East and Africa

      • 4.1.5. Top Five Countries Contributing to Clinical Trials in Central and South America

      • 4.1.6. Clinical Trials by G7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials

  • 5. Clinical Trials by Phase in G7 Countries

  • 6. Clinical Trials in G7 Countries by Trial Status

  • 7. Clinical Trials by E7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials

  • 8. Clinical Trials by Phase in E7 Countries

  • 9. Clinical Trials in E7 Countries by Trial Status

  • 10. Clinical Trials by Phase

    • 10.1. In Progress Trials by Phase

  • 11. Clinical Trials by Trial Status

  • 12. Clinical Trials by End Point Status

  • 13. Subjects Recruited Over a Period of Time

  • 14. Clinical Trials by Sponsor Type

  • 15. Prominent Sponsors

    • 15.1. Top Companies Participating in Refractory Multiple Myeloma Therapeutics Clinical Trials

  • 16. Prominent Drugs

  • 17. Latest Clinical Trials News on Refractory Multiple Myeloma

    • 17.1. Nov 14, 2024: Blenrep Shows Overall Survival Benefit in Head-To-Head Dreamm-7 Phase III Trial for Relapsed/Refractory Multiple Myeloma

    • 17.2. Nov 06, 2024: Carsgen to Present Zevor-Cel at ASH 2024 Annual Congress

    • 17.3. Nov 06, 2024: Carsgen to Present CT0590 at ASH 2024 Annual Congress

    • 17.4. Nov 05, 2024: Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific Isb 2001 in r/rMM at Upcoming ASH

    • 17.5. Nov 05, 2024: Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 1442 in r/r MM at Upcoming ASH

    • 17.6. Nov 05, 2024: Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

    • 17.7. Nov 05, 2024: Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

    • 17.8. Nov 05, 2024: Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Multiple Myeloma at the 66th ASH Annual Meeting

    • 17.9. Oct 08, 2024: Aurigene Oncology Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

    • 17.10. Sep 27, 2024: Novel Combination of Talvey Suggests High Response Rates and Durable Responses in Triple-Class Refractory Patients with R/R Multiple Myeloma

    • 17.11. Sep 27, 2024: Novel Combination of Tecvayli Suggests High Response Rates and Durable Responses in Triple-Class Refractory Patients with R/R Multiple Myeloma

    • 17.12. Sep 27, 2024: IASO Bio Presented the Outcomes of R/Rmm Patients with Renal Impairment Treated with Equecabtagene Autoleucel at 2024 IMS Annual Meeting

    • 17.13. Sep 27, 2024: Talvey and Darzalex Faspro Based Combination Shows Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma

    • 17.14. Sep 27, 2024: Poseida Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in RRMM Patients

    • 17.15. Sep 17, 2024: Blenrep (belantamab mafodotin) Combinations in Relapsed/Refractory Multiple Myeloma Accepted for Regulatory Review in Japan

    • 17.16. Sep 16, 2024: China grants BTD to Blenrep with BorDex for multiple myeloma

    • 17.17. Sep 16, 2024: FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

    • 17.18. Sep 11, 2024: IGI Announces Publication in Nature Cancer on ISB 2001, IGI’s Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

    • 17.19. Sep 05, 2024: Poseida to Present Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed/Refractory Multiple Myeloma at 21st IMS Annual Meeting

  • 18. Clinical Trial Profile Snapshots

    • 18.1. Abbreviations

    • 18.2. Definitions

    • 18.3. Research Methodology

    • 18.4. Secondary Research

    • 18.5. About GlobalData

    • 18.6. Contact Us

    • 18.7. Disclaimer

    • 18.8. Source

Table

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2024* 8

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024* 10

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024* 11

Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024* 12

Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2024* 13

Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2024* 14

Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024* 15

Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024* 16

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2024* 17

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2024* 18

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024* 20

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2024* 21

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2024* 22

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024* 24

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2024* 25

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2024* 26

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2024* 28

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2024* 29

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023 30

Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024* 31

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2024* 33

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024* 34

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024* 35

Figures

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2024* 8

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024* 9

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024* 11

Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024* 12

Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024* 13

Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2024* 14

Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024* 15

Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024* 16

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2024* 17

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2024* 18

Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024* 19

Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2024* 21

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2024* 22

Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024* 23

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2024* 25

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2024* 26

Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2024* 27

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2024* 29

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023 30

Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024* 31

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2024* 32

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024* 34

Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024* 35

GlobalData Methodology 1065

Frequently asked questions

Refractory Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update standard reports
Currency USD
$3,450

Can be used by individual purchaser only

Most Popular
$6,900

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,350

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Refractory Multiple Myeloma reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Refractory Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update in real time.

  • Access a live Refractory Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more